Skip to main content

Table 1 General characteristics of the study population

From: Differential effect of statin use on coagulation markers: an active comparative analysis in the NEO study

General characteristics Fibrate /Niacin (n = 22) Fluvastatin (n = 10) Pravastatin (n = 114) Simvastatin ± Ezetimab (n = 612) Atorvastatin (n = 181) Rosuvastatin (n = 104)
Mean age, Y (SD) 57.5 ± 4.7 62.3 ± 5.5 58.1 ± 5.2 58.3 ± 5.2 59.0 ± 4.6 57.7 ± 5.5
Men, n (%) 13 (59.1) 4 (40) 71 (62.3) 352 (57.5) 126 (69.6) 72 (69.2)
Mean BMI, kg/m2 (SD) 31.0 ± 2.8 31.8 ± 4.9 31.3 ± 4.5 31.1 ± 4.4 31.4 ± 4.8 31.6 ± 4.7
Smoking history, n (%) 18 (85.7) 8 (80) 86 (75.4) 451 (73.8) 141 (78.3) 86 (82.7)
HTN (Yes), n (%) 10 (45.5) 8 (80) 53 (46.5) 255 (41.7) 88 (48.6) 46 (44.7)
Diabetes (Yes), n (%) 7 (31.8) 6 (60) 39 (34.2) 224 (37) 66 (36.9) 24 (23.5)
CVD (yes), n (%) 3 (13.6) 5 (50) 37 (32.7) 119 (19.5) 77 (43) 39 (38.2)
  1. BMI denotes body mass index, CVD cardiovascular diseases, HTN hypertension
  2. Age and BMI are presented as mean ± standard deviation (SD)